NOX — Noxopharm Income Statement
0.000.00%
Last trade - 00:00- AU$22.50m
- AU$23.43m
- AU$2.83m
Annual income statement for Noxopharm, fiscal year end - June 30th, AUD millions except per share, conversion factor applied.
2021 June 30th | 2022 June 30th | 2023 June 30th | 2024 June 30th | 2025 June 30th | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 5.75 | 5.45 | 6.07 | 2.41 | 2.83 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Total Operating Expenses | 20.2 | 15.2 | 16.7 | 7 | 8.21 |
| Operating Profit | -14.5 | -9.76 | -10.6 | -4.59 | -5.38 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -9.35 | -18.7 | -15.1 | -3.58 | -4.88 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -9.35 | -18.7 | -15.1 | -3.58 | -4.88 |
| Minority Interest | |||||
| Net Income Before Extraordinary Items | |||||
| Net Income | -9.35 | -18.7 | -15.1 | -3.58 | -4.88 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -9.35 | -18.7 | -15.1 | -3.58 | -4.88 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.035 | -0.064 | -0.052 | -0.012 | -0.017 |